Bach: Part B change could stem price hikes, hurt oncologists

In a Memorial Sloan Kettering Cancer Center.

The report said the proposed reimbursement change could dissuade manufacturers from raising prices because the payment rate for infused drugs is

Read the full 288 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE